1. [CASE 1 — QUESTION 1]
A 47-year-old man presents with several months of worsening headaches, reduced peripheral vision, and decreased libido. On examination he has a bitemporal visual field deficit. Pituitary MRI reveals a 34 mm sellar mass with suprasellar extension compressing the optic chiasm. Initial laboratory testing shows a serum prolactin of 52 ng/mL (upper limit of normal approximately 20 ng/mL), a low morning testosterone, and otherwise intact anterior pituitary function. The neurosurgical team is preparing to schedule decompressive transsphenoidal surgery for a presumed clinically nonfunctioning macroadenoma. Which of the following is the most appropriate next step before committing this patient to surgery?
A) Proceed directly to transsphenoidal surgery, because a large sellar mass with a prolactin only mildly above normal establishes a nonfunctioning adenoma with stalk-effect hyperprolactinemia that will not respond to medical therapy.
B) Begin empiric high-dose glucocorticoids for presumed lymphocytic hypophysitis, because the combination of a sellar mass and hypogonadism is most consistent with an inflammatory rather than neoplastic process.
C) Request a 1:100 serial dilution of the serum prolactin before surgery, because a very large pituitary mass accompanied by only a mildly elevated prolactin is the classic presentation of the hook effect, in which extremely high prolactin saturates the immunometric assay and produces a falsely low value; unmasking a markedly elevated true prolactin would identify a macroprolactinoma treatable first with a dopamine agonist.
D) Obtain a serum insulin-like growth factor-1 (IGF-1) level, because the most likely diagnosis is a growth hormone-secreting macroadenoma and confirming acromegaly would direct therapy to a somatostatin analog.
E) Measure 24-hour urinary free cortisol (UFC), because the hypogonadism and mass effect suggest Cushing disease, and confirming hypercortisolism would direct therapy to a steroidogenesis inhibitor.
ANSWER: C
Rationale:
This presentation is the classic clinical trap for the hook effect. A very large sellar mass (34 mm) with chiasmal compression but only a mildly elevated prolactin (52 ng/mL) should raise immediate suspicion that the immunometric assay has been saturated by an extremely high prolactin concentration, producing a falsely low measured value. The correct next step is a serial dilution of the serum (typically 1:100) before committing to surgery; if the diluted value rises markedly, the lesion is a macroprolactinoma. This distinction is critical because a macroprolactinoma is treated first with a dopamine agonist such as cabergoline, which shrinks the tumor in the large majority of patients and can relieve chiasmal compression and restore vision without an operation.
Option A: Option A is incorrect because the mildly elevated prolactin in the presence of a very large mass should not be assumed to represent stalk effect; stalk-effect hyperprolactinemia generally produces values below about 150 to 200 ng/mL, and the hook effect must be excluded by dilution before attributing a large mass to a nonfunctioning adenoma.
Option B: Option B is incorrect because the clinical picture of a large sellar mass with chiasmal compression is far more consistent with a macroadenoma than with hypophysitis, and empiric glucocorticoids would neither diagnose nor treat a masked macroprolactinoma.
Option D: Option D is incorrect because, although IGF-1 is a reasonable part of a complete pituitary workup, the immediate decision point is whether the mass is a macroprolactinoma masked by the hook effect, since that single finding could replace surgery with medical therapy; nothing in the vignette specifically suggests acromegaly.
Option E: Option E is incorrect because there are no features of cortisol excess in this patient, and measuring UFC would not address the central question of whether a hook effect is masking a macroprolactinoma that could be treated medically.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. A 1:100 serial dilution reveals a true serum prolactin of 7,400 ng/mL, confirming a macroprolactinoma. He is started on cabergoline rather than referred for immediate surgery. Which of the following best describes the mechanism and the expected therapeutic goals of this treatment choice?
A) Cabergoline activates dopamine D2 receptors (D2R) on lactotroph adenoma cells — a Gi-coupled pathway that lowers cyclic AMP (cAMP) and suppresses prolactin secretion — and also produces direct antiproliferative effects; the expected goals are normalization of prolactin, reduction of tumor volume to relieve chiasmal compression and restore vision, and recovery of gonadal function, often avoiding surgery.
B) Cabergoline blocks pituitary prolactin receptors, preventing autocrine prolactin stimulation of the lactotroph; the goal is symptomatic relief of galactorrhea without any effect on tumor size.
C) Cabergoline inhibits adrenal steroidogenesis through CYP11B1 blockade, lowering cortisol; the goal is to reduce the metabolic consequences of the sellar mass.
D) Cabergoline stimulates serotonin 5-HT2B receptors on lactotrophs to suppress prolactin; the goal is rapid prolactin normalization, with tumor shrinkage being mediated by the same receptor.
E) Cabergoline acts as a somatostatin receptor agonist at the lactotroph; the goal is to suppress prolactin secretion while leaving tumor volume unchanged, with surgery still required for decompression.
ANSWER: A
Rationale:
Cabergoline is the first-line therapy for a macroprolactinoma, and its mechanism explains why medical therapy can replace surgery even with chiasmal compression. Cabergoline activates dopamine D2 receptors (D2R) on lactotroph adenoma cells; D2R is Gi-coupled, so activation inhibits adenylyl cyclase, lowers cyclic AMP (cAMP), and suppresses prolactin transcription and secretion. Sustained D2R activation also produces direct antiproliferative effects, leading to tumor volume reduction in 80 to 90% of patients. The therapeutic goals in this patient are normalization of prolactin, reduction of tumor volume to relieve compression of the optic chiasm and restore vision, and recovery of gonadal function — frequently achieved without surgery.
Option B: Option B is incorrect because cabergoline is a dopamine receptor agonist, not a prolactin receptor antagonist, and it does reduce tumor volume rather than merely relieving galactorrhea; prolactin receptors mediate peripheral prolactin effects, not the secretory feedback targeted here.
Option C: Option C is incorrect because cabergoline does not inhibit adrenal steroidogenesis or block CYP11B1; that is the mechanism of steroidogenesis inhibitors used in Cushing disease, not a dopamine agonist used for prolactinoma.
Option D: Option D is incorrect because prolactin suppression is mediated by D2R, not by 5-HT2B receptors; 5-HT2B activation on cardiac valve fibroblasts mediates cabergoline's valvulopathy risk and is unrelated to its therapeutic prolactin-lowering mechanism.
Option E: Option E is incorrect because cabergoline is a dopamine agonist rather than a somatostatin receptor agonist, and it does reduce tumor volume; a macroprolactinoma typically shrinks with cabergoline, so surgery is not necessarily required for decompression.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Over the next several months his prolactin falls and his vision improves, but residual tumor and incomplete prolactin normalization prompt the team to escalate cabergoline from 1 mg per week toward 3 mg per week. Which of the following is the most appropriate surveillance action related to the principal long-term safety concern of cabergoline at this higher dose, and what is its mechanistic basis?
A) Obtain serial liver function tests (LFTs), because the principal dose-limiting toxicity of cabergoline at higher doses is hepatotoxicity mediated by reactive metabolite formation.
B) Obtain serial 12-lead electrocardiograms (ECGs) to monitor for QT prolongation, because cabergoline's principal dose-dependent toxicity is hERG channel blockade.
C) Obtain pulmonary function tests and chest imaging, because the principal dose-dependent toxicity of cabergoline is pleuropulmonary fibrosis that must be excluded before any dose increase.
D) No additional surveillance is required, because cabergoline valvulopathy occurs only at the very high daily doses used in Parkinson disease and cannot occur at any dose used for prolactinoma.
E) Obtain a baseline echocardiogram before escalating the dose, because cabergoline's principal long-term safety concern is cardiac valvulopathy mediated by agonism at serotonin 5-HT2B receptors on cardiac valve fibroblasts; cumulative exposure governs the risk, and surveillance echocardiography is recommended particularly when the weekly dose exceeds 2 mg.
ANSWER: E
Rationale:
The principal long-term safety concern with cabergoline is cardiac valvulopathy — fibrotic thickening of cardiac valve leaflets with regurgitation — mediated by agonism at serotonin 5-HT2B receptors on cardiac valve interstitial fibroblasts. This is a non-D2R effect, distinct from the therapeutic mechanism, and the risk is driven by cumulative drug exposure. Guidelines recommend baseline echocardiography before starting or escalating cabergoline, with periodic surveillance, particularly when the weekly dose exceeds 2 mg. Escalating this patient toward 3 mg per week crosses that threshold, making a baseline echocardiogram the appropriate surveillance step.
Option A: Option A is incorrect because hepatotoxicity is the dose-limiting toxicity of ketoconazole, not cabergoline; cabergoline does not require routine LFT monitoring as its principal safety surveillance, and a reactive-metabolite hepatotoxicity mechanism is not characteristic of it.
Option B: Option B is incorrect because QT prolongation via hERG channel blockade is a concern for steroidogenesis inhibitors such as ketoconazole and osilodrostat, not the principal dose-dependent toxicity of cabergoline; cabergoline surveillance centers on valvular rather than electrophysiologic monitoring.
Option C: Option C is incorrect because, although pleuropulmonary and retroperitoneal fibrosis are rare recognized complications of long-term high-dose ergot dopamine agonist use, they are not the principal surveillance focus at prolactinoma doses; cardiac valvulopathy and echocardiographic monitoring are.
Option D: Option D is incorrect because, although valvulopathy risk is much lower at prolactinoma doses than at Parkinson disease doses, it is not impossible, and guidelines specifically recommend echocardiographic surveillance above 2 mg per week; dismissing surveillance entirely contradicts that recommendation.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Two years later, his serum prolactin has been normal for the past 24 months and his most recent MRI shows no visible tumor. His vision has fully recovered. He asks whether he can stop cabergoline. Which of the following is the most appropriate plan regarding withdrawal and subsequent monitoring?
A) He must continue cabergoline indefinitely, because macroprolactinomas always recur after withdrawal regardless of prolactin level or MRI findings, so discontinuation is never appropriate.
B) He meets withdrawal candidacy criteria — at least 2 years of sustained normoprolactinemia and no visible tumor on MRI — so cabergoline can be tapered and discontinued; after withdrawal, prolactin should be monitored at 1, 3, and 6 months and then annually, recognizing that recurrence is common (roughly 30 to 35% within the first year and up to about 70% by 5 years) and is managed by restarting cabergoline, to which response is generally preserved. Patients with prior macroprolactinomas carry higher recurrence risk and require close follow-up.
C) Cabergoline can be stopped abruptly with no scheduled monitoring, because an undetectable tumor on MRI guarantees permanent remission and recurrence does not occur once the tumor is no longer visible.
D) Withdrawal should be deferred until he has completed at least 10 years of therapy, because recurrence rates remain above 90% before that point irrespective of prolactin or imaging status.
E) Cabergoline should be replaced with low-dose bromocriptine indefinitely, because switching agents at this stage eliminates recurrence risk while reducing valvulopathy exposure.
ANSWER: B
Rationale:
The standard candidacy criteria for cabergoline withdrawal are at least 2 years of sustained normoprolactinemia and no visible tumor (or at most minimal residual change) on MRI; this patient satisfies both. The appropriate plan is to taper and discontinue cabergoline, then monitor prolactin at 1, 3, and 6 months and annually thereafter. Counseling must include that recurrence is common — approximately 30 to 35% within the first year and up to about 70% by 5 years — and that recurrence is managed by restarting cabergoline, with response generally preserved. Importantly, patients with prior macroprolactinomas (as here) carry a higher recurrence risk than those with microadenomas and require particularly close follow-up; some may ultimately require indefinite therapy.
Option A: Option A is incorrect because withdrawal is appropriate in eligible patients; while macroprolactinomas carry higher recurrence risk, discontinuation is not categorically prohibited, and many patients can attempt withdrawal with structured monitoring.
Option C: Option C is incorrect because scheduled biochemical monitoring is required after withdrawal rather than relying on the assumption of permanent remission; an undetectable tumor on MRI does not guarantee that prolactin will remain normal, and recurrence does occur.
Option D: Option D is incorrect because the threshold for withdrawal candidacy is 2 years of sustained normoprolactinemia with a clear MRI, not a 10-year treatment duration; the inflated recurrence figure is incorrect.
Option E: Option E is incorrect because switching to bromocriptine does not eliminate recurrence risk, and bromocriptine is less potent and less well tolerated than cabergoline; there is no rationale for indefinite bromocriptine in an eligible withdrawal candidate.
5. [CASE 2 — QUESTION 5]
A 54-year-old man with acromegaly due to a 24 mm somatotroph macroadenoma has undergone transsphenoidal surgery with only partial debulking. He has been on octreotide long-acting release (LAR) at maximum dose for 9 months, but his insulin-like growth factor-1 (IGF-1) remains elevated at 1.8 times the upper limit of normal. His serum prolactin is also elevated, above the normal male range. The team considers adding cabergoline to his somatostatin analog (SSA) regimen. Which of the following best explains why the elevated serum prolactin increases the likelihood that adding cabergoline will help?
A) Elevated prolactin indicates that the tumor is a pure prolactinoma rather than a somatotroph adenoma, so cabergoline will normalize both prolactin and IGF-1 by acting on the dominant lactotroph component, and the SSA can be discontinued.
B) Elevated prolactin reflects increased somatostatin receptor subtype 2 (SSTR2) expression, which predicts that adding cabergoline will potentiate the SSA's somatostatinergic effect on growth hormone secretion.
C) Elevated prolactin indicates stalk compression from the macroadenoma and is unrelated to receptor expression, so it provides no information about the likelihood of a cabergoline response.
D) Elevated prolactin in a somatotroph adenoma suggests co-secretion of growth hormone and prolactin from a mixed lactosomatotroph tumor that expresses dopamine D2 receptors (D2R) at levels sufficient to respond to cabergoline; tumors with elevated prolactin have a higher likelihood of D2R expression and thus a higher probability of additive IGF-1 reduction with dopamine agonism added to the SSA.
E) Elevated prolactin indicates that cabergoline will lower IGF-1 by directly inhibiting hepatic IGF-1 synthesis, independent of any pituitary receptor, so tumor receptor expression is irrelevant to the prediction.
ANSWER: D
Rationale:
In acromegaly, dopamine agonists produce weaker growth hormone suppression than somatostatin analogs because most somatotroph adenomas predominantly express SSTR2 and SSTR5 rather than dopamine D2 receptors (D2R). However, a subset of somatotroph adenomas are mixed lactosomatotroph tumors that co-secrete growth hormone and prolactin and that express D2R at levels sufficient to respond to cabergoline. An elevated serum prolactin in a patient with acromegaly is therefore a useful clinical marker suggesting D2R expression, and published series confirm that such patients have a higher likelihood of additive IGF-1 reduction when cabergoline is added to an SSA. Cabergoline add-on to SSA therapy produces additive IGF-1 reduction in roughly 50 to 60% of patients with partial SSA resistance, particularly those with elevated prolactin.
Option A: Option A is incorrect because the elevated prolactin reflects a mixed lactosomatotroph tumor, not a pure prolactinoma; the dominant clinical disease is acromegaly, cabergoline produces only modest IGF-1 effects, and the SSA should not be discontinued.
Option B: Option B is incorrect because elevated prolactin does not indicate increased SSTR2 expression; cabergoline acts through D2R, not by potentiating somatostatin receptor signaling, so the rationale is dopaminergic responsiveness, not SSTR2 potentiation.
Option C: Option C is incorrect because in this setting elevated prolactin reflects co-secretion from a D2R-expressing mixed tumor and does carry predictive value for cabergoline response, rather than being uninformative stalk-effect hyperprolactinemia.
Option E: Option E is incorrect because cabergoline does not directly inhibit hepatic IGF-1 synthesis; it acts at pituitary D2 receptors to reduce growth hormone secretion from D2R-expressing tumors, so tumor receptor expression and the prolactin marker are central to predicting response.
6. [CASE 2 — QUESTION 6]
Continuing with the same patient. Despite adding cabergoline, both his growth hormone and IGF-1 remain clearly elevated, and follow-up imaging shows the residual tumor has not decreased in size. The team now considers switching from the first-generation somatostatin analog to pasireotide. Which of the following best describes the rationale for this step, based on the evidence from the pivotal trial of pasireotide in acromegaly?
A) Pasireotide should be avoided because it has no greater efficacy than first-generation somatostatin analogs in patients with inadequate control, and switching offers no biochemical advantage.
B) Pasireotide is a reasonable next step because, in the pivotal PAOLA (Pasireotide versus Octreotide/Lanreotide in Acromegaly) trial, pasireotide long-acting release produced biochemical control of growth hormone and IGF-1 in a meaningfully higher proportion of patients inadequately controlled on first-generation somatostatin analogs than switching to the alternative first-generation agent, making it appropriate when both growth hormone and IGF-1 remain elevated and tumor volume reduction is still needed; the trade-off is a substantially higher rate of hyperglycemia that must be managed.
C) Pasireotide should be chosen specifically because it does not cause hyperglycemia, unlike first-generation somatostatin analogs, so it is the safest metabolic option for this patient.
D) Pasireotide acts by blocking growth hormone receptors in peripheral tissues, normalizing IGF-1 without affecting the pituitary tumor, so it is preferred when tumor shrinkage is not a goal.
E) Pasireotide is preferred because it lowers IGF-1 through dopamine D2 receptor agonism that is more potent than cabergoline, so it can replace both the somatostatin analog and the dopamine agonist.
ANSWER: B
Rationale:
Pasireotide is the appropriate pharmacological option when first-generation somatostatin analogs fail to control growth hormone and IGF-1 in acromegaly. In the pivotal PAOLA trial, pasireotide long-acting release (40 mg and 60 mg monthly) produced biochemical control — normal growth hormone and IGF-1 — in a meaningfully higher proportion of patients inadequately controlled on first-generation somatostatin analogs (roughly 31 to 38%) than switching to the alternative first-generation agent (about 19%). This makes pasireotide a rational next step when both growth hormone and IGF-1 remain elevated and tumor volume reduction is still needed, because somatostatin analogs (including pasireotide) can reduce tumor volume. The key trade-off is a substantially higher rate of hyperglycemia (occurring in a majority of patients), which must be anticipated and managed.
Option A: Option A is incorrect because PAOLA demonstrated greater efficacy for pasireotide than for switching to an alternative first-generation agent in inadequately controlled patients, so it does offer a biochemical advantage.
Option C: Option C is incorrect because pasireotide causes more, not less, hyperglycemia than first-generation somatostatin analogs; reduced hyperglycemia is not a reason to choose it, and its metabolic burden is in fact its principal drawback.
Option D: Option D is incorrect because pasireotide is a somatostatin receptor agonist acting at the pituitary, not a growth hormone receptor blocker; peripheral growth hormone receptor antagonism is the mechanism of pegvisomant, which does not reduce tumor volume.
Option E: Option E is incorrect because pasireotide acts through somatostatin receptors, not dopamine D2 receptors; it does not work through a more potent dopaminergic mechanism and does not substitute for the dopamine agonist by that route.
7. [CASE 2 — QUESTION 7]
Continuing with the same patient. Six weeks after switching to pasireotide, his IGF-1 has improved, but his fasting glucose is now 192 mg/dL and his HbA1c has risen to 8.0%; he had no prior diagnosis of diabetes. The team wishes to continue pasireotide for its biochemical benefit. Which of the following is the most appropriate management of his hyperglycemia and its pharmacological rationale?
A) Start a glucagon-like peptide-1 (GLP-1) receptor agonist as the preferred first-line agent, because pasireotide causes hyperglycemia chiefly by suppressing insulin secretion through somatostatin receptors on the pancreatic islet, and GLP-1 receptor agonists stimulate insulin secretion and suppress glucagon through GLP-1 receptor signaling that remains effective despite somatostatin receptor activation, allowing pasireotide to be continued.
B) Discontinue pasireotide immediately, because any treatment-emergent hyperglycemia indicates the drug cannot be safely continued, and revert to the first-generation somatostatin analog.
C) Start a sulfonylurea as first-line therapy, because forcing maximal insulin secretion fully overcomes the somatostatin receptor-mediated suppression caused by pasireotide.
D) Start a thiazolidinedione as first-line therapy, because pasireotide-induced hyperglycemia is driven primarily by peripheral insulin resistance that insulin sensitizers directly reverse.
E) Make no change and continue monitoring, because pasireotide-induced hyperglycemia is self-limited and resolves without pharmacological treatment in nearly all patients.
ANSWER: A
Rationale:
Pasireotide-induced hyperglycemia is common in acromegaly patients and results chiefly from somatostatin receptor-mediated suppression of pancreatic insulin secretion, along with impaired incretin and glucagon regulation. When the drug provides meaningful biochemical control, as here, the appropriate approach is to manage the hyperglycemia pharmacologically rather than abandon effective therapy. GLP-1 receptor agonists are the preferred first-line agents because they stimulate insulin secretion and suppress glucagon through GLP-1 receptor signaling that remains effective despite somatostatin receptor activation, directly countering the mechanism of pasireotide-induced hyperglycemia and allowing pasireotide to continue.
Option B: Option B is incorrect because treatment-emergent hyperglycemia does not require immediate discontinuation of effective pasireotide therapy; the hyperglycemia is anticipated and managed with preferred agents.
Option C: Option C is incorrect because sulfonylurea-stimulated insulin release is partially blunted by concurrent somatostatin receptor activation, making sulfonylureas less effective than GLP-1 receptor agonists in this setting.
Option D: Option D is incorrect because the primary driver of pasireotide-induced hyperglycemia is impaired insulin secretion rather than peripheral insulin resistance, so thiazolidinediones do not address the central defect and are not first-line.
Option E: Option E is incorrect because pasireotide-induced hyperglycemia is common and often requires active management rather than resolving spontaneously; leaving an HbA1c of 8.0% untreated would be inappropriate.
8. [CASE 2 — QUESTION 8]
Continuing with the same patient. The team reviews the broader menu of options for SSA-resistant acromegaly and wants to clarify when pegvisomant, pasireotide, and cabergoline are each most appropriate. Which of the following best summarizes the selection logic among these agents?
A) Pegvisomant is preferred whenever any residual tumor remains, because it produces the greatest tumor volume reduction of the three agents and normalizes both growth hormone and IGF-1 simultaneously.
B) Cabergoline is the best choice for all SSA-resistant patients regardless of prolactin status, because it is the most potent agent for lowering both growth hormone and IGF-1.
C) Cabergoline add-on is best when serum prolactin is elevated or IGF-1 is only mildly above normal and the lowest risk of new adverse effects is desired; pasireotide is chosen when both growth hormone and IGF-1 remain clearly elevated and tumor volume reduction is still needed, accepting the hyperglycemia burden; and pegvisomant is chosen when IGF-1 alone remains elevated with growth hormone controlled, when pasireotide-related hyperglycemia is unacceptable, or when maximal IGF-1 normalization is the priority — but pegvisomant requires monitoring because it does not reduce tumor volume.
D) Pasireotide and pegvisomant are interchangeable because both act by blocking growth hormone receptors peripherally, so the choice between them is based solely on dosing convenience.
E) Pegvisomant lowers IGF-1 by suppressing pituitary growth hormone secretion through somatostatin receptors, so it reduces tumor volume similarly to pasireotide and is preferred when shrinkage is needed.
ANSWER: C
Rationale:
The selection logic among the three agents for SSA-resistant acromegaly reflects their distinct mechanisms and trade-offs. Cabergoline add-on is best when serum prolactin is elevated (suggesting D2R expression) or when IGF-1 is only mildly above normal, and when the lowest risk of new adverse effects is desired. Pasireotide is chosen when both growth hormone and IGF-1 remain clearly elevated and tumor volume reduction is still needed, accepting the substantial hyperglycemia management burden. Pegvisomant — a growth hormone receptor antagonist acting peripherally — is chosen when IGF-1 alone remains elevated with growth hormone controlled, when pasireotide-related hyperglycemia is unacceptable, or when maximal IGF-1 normalization is the priority; however, because pegvisomant does not act on the pituitary tumor, it does not reduce tumor volume and requires periodic pituitary MRI surveillance.
Option A: Option A is incorrect because pegvisomant does not reduce tumor volume — it acts peripherally at growth hormone receptors and requires MRI monitoring for tumor growth — so it is not preferred merely because residual tumor remains.
Option B: Option B is incorrect because cabergoline is not the most potent option for all patients; its efficacy is modest and is best in those with elevated prolactin or mildly elevated IGF-1, so prolactin status does matter.
Option D: Option D is incorrect because pasireotide and pegvisomant are not interchangeable and do not share a mechanism: pasireotide is a somatostatin receptor agonist acting at the pituitary, whereas pegvisomant is a peripheral growth hormone receptor antagonist.
Option E: Option E is incorrect because pegvisomant does not suppress pituitary growth hormone secretion through somatostatin receptors and does not reduce tumor volume; it blocks growth hormone action at peripheral receptors, which is precisely why tumor surveillance is required.
9. [CASE 3 — QUESTION 9]
A 50-year-old woman with Cushing disease has persistent severe hypercortisolism after an unsuccessful transsphenoidal surgery, with a urinary free cortisol (UFC) more than 6 times the upper limit of normal, hypertension, hyperglycemia, and hirsutism. The team initiates ketoconazole to lower cortisol while planning further intervention. Which of the following correctly identifies ketoconazole's principal adrenal enzymatic target and the organ-specific toxicity that must be monitored during therapy?
A) Its principal target is CYP11B2 (aldosterone synthase), and the toxicity requiring monitoring is hyperkalemia from aldosterone deficiency; potassium should be checked weekly.
B) Its principal target is CYP11B1 (11-beta-hydroxylase), and the toxicity requiring monitoring is mineralocorticoid excess from 11-deoxycorticosterone (DOC) accumulation; blood pressure and potassium should be monitored.
C) Its principal target is 3-beta-hydroxysteroid dehydrogenase, and the toxicity requiring monitoring is bone marrow suppression; a complete blood count should be checked every 2 weeks.
D) Its principal target is CYP11A1 (cholesterol side-chain cleavage enzyme), and the toxicity requiring monitoring is nephrotoxicity; serum creatinine should be checked weekly.
E) Its most potent adrenal target is CYP17A1 (17-alpha-hydroxylase/17,20-lyase), which participates in both cortisol and androgen synthesis (so ketoconazole lowers cortisol and may also improve hirsutism); the principal organ-specific toxicity requiring monitoring is hepatotoxicity, with liver function tests checked every 2 to 4 weeks during initiation and monthly thereafter, and discontinuation if significant enzyme elevation or clinical hepatotoxicity develops.
ANSWER: E
Rationale:
Ketoconazole inhibits several adrenal cytochrome P450 enzymes, but its most potent inhibitory effect is at CYP17A1 (17-alpha-hydroxylase/17,20-lyase), which contributes to both cortisol synthesis and androgen synthesis; consequently ketoconazole lowers cortisol and can also reduce adrenal androgens, potentially improving androgen-driven hirsutism. The principal organ-specific toxicity is hepatotoxicity: ketoconazole causes elevated liver enzymes in up to roughly 20% of patients and severe hepatotoxicity in a smaller subset, so liver function tests must be monitored every 2 to 4 weeks during initiation and monthly thereafter, with discontinuation if significant transaminase elevation or clinical hepatotoxicity develops. This monitoring requirement is a defining feature of ketoconazole therapy in Cushing disease.
Option A: Option A is incorrect because CYP11B2 (aldosterone synthase) is not ketoconazole's principal target, and aldosterone-deficiency hyperkalemia is associated with osilodrostat, not ketoconazole.
Option B: Option B is incorrect because CYP11B1 is the selective target of metyrapone, not the most potent target of ketoconazole, and DOC-driven mineralocorticoid excess is the characteristic adverse effect of metyrapone rather than ketoconazole.
Option C: Option C is incorrect because 3-beta-hydroxysteroid dehydrogenase is not a cytochrome P450 enzyme or a significant ketoconazole target, and bone marrow suppression is not the principal toxicity of ketoconazole.
Option D: Option D is incorrect because, although ketoconazole does inhibit CYP11A1 to some degree, it is not the most potent target, and nephrotoxicity is not the defining organ toxicity; hepatotoxicity is.
10. [CASE 3 — QUESTION 10]
Continuing with the same patient. It emerges that she received a kidney transplant 2 years ago and is maintained on tacrolimus. The team is concerned about a drug interaction with the newly started ketoconazole. Which of the following best describes the most important interaction and the appropriate management approach?
A) Ketoconazole induces CYP3A4, lowering tacrolimus levels and risking transplant rejection, so the tacrolimus dose should be increased empirically without monitoring.
B) Ketoconazole is a strong CYP3A4 (cytochrome P450 3A4) inhibitor and tacrolimus is a CYP3A4 substrate, so co-administration markedly increases tacrolimus concentrations and the risk of nephrotoxicity and neurotoxicity; if ketoconazole is used it requires substantial tacrolimus dose reduction with frequent trough monitoring, and a cortisol-lowering agent with fewer CYP3A4 interactions (such as metyrapone or osilodrostat) may be preferable in this transplant patient.
C) Tacrolimus and ketoconazole have no clinically meaningful interaction because tacrolimus is eliminated unchanged by the kidney, so no dose adjustment is required.
D) Ketoconazole displaces tacrolimus from plasma protein binding, transiently raising free tacrolimus without a meaningful change in total clearance, so only brief monitoring is needed.
E) The only relevant concern is additive nephrotoxicity between tacrolimus and ketoconazole through a shared tubular mechanism, with no cytochrome-based interaction involved.
ANSWER: B
Rationale:
The critical interaction is between ketoconazole and tacrolimus. Ketoconazole is a strong inhibitor of CYP3A4, the principal enzyme responsible for tacrolimus metabolism, so co-administration dramatically increases tacrolimus concentrations and the risk of tacrolimus toxicity — nephrotoxicity and neurotoxicity — at previously stable doses. If ketoconazole is used, it requires substantial tacrolimus dose reduction (often 50% or more) with frequent trough monitoring; alternatively, a cortisol-lowering agent with fewer CYP3A4 interactions, such as metyrapone or osilodrostat, may be preferable in a transplant patient to avoid destabilizing immunosuppression. Anticipating this interaction and either monitoring intensively or choosing a less-interacting agent is the appropriate management.
Option A: Option A is incorrect because ketoconazole inhibits rather than induces CYP3A4; inhibition raises tacrolimus levels, so the dose must be reduced with monitoring, not increased empirically.
Option C: Option C is incorrect because tacrolimus is extensively metabolized by hepatic CYP3A4, not eliminated unchanged renally, so there is a major, clinically significant interaction requiring dose adjustment and monitoring.
Option D: Option D is incorrect because the dominant mechanism is CYP3A4 metabolic inhibition rather than plasma protein displacement; the magnitude of the tacrolimus rise reflects reduced clearance, not transient protein-binding changes.
Option E: Option E is incorrect because the principal concern is the CYP3A4-mediated metabolic interaction increasing tacrolimus exposure; a shared tubular nephrotoxic mechanism without a cytochrome interaction does not describe this combination.
11. [CASE 3 — QUESTION 11]
Continuing with the same patient. To avoid the tacrolimus interaction, ketoconazole is stopped and she is switched to metyrapone. After several weeks, her UFC has fallen appropriately and her cushingoid features are improving, but she develops a blood pressure of 160/98 mmHg (previously well controlled) and a serum potassium of 3.0 mEq/L. Which of the following best explains these new findings?
A) The findings indicate metyrapone treatment failure with worsening cortisol excess, so metyrapone should be stopped, as the falling UFC must be a laboratory error.
B) The findings indicate adrenal insufficiency from over-suppression of cortisol, since hypertension and hypokalemia are the classic features of glucocorticoid deficiency.
C) The hypertension and hypokalemia are caused by residual ketoconazole-induced CYP3A4 inhibition raising the levels of her antihypertensive medications.
D) Metyrapone's block of CYP11B1 (11-beta-hydroxylase) prevents conversion of 11-deoxycorticosterone (DOC) to corticosterone, so DOC accumulates; because rising ACTH (from falling cortisol feedback) drives more precursor through the blocked pathway, DOC-mediated mineralocorticoid activity increases, producing hypertension and hypokalemia even as cortisol falls — the drug can be continued for cortisol control while the blood pressure and potassium are managed.
E) The findings reflect pasireotide-type islet suppression causing hyperglycemia, and the electrolyte changes are secondary to osmotic diuresis.
ANSWER: D
Rationale:
This is the characteristic pattern of metyrapone-associated mineralocorticoid excess. Metyrapone inhibits CYP11B1 (11-beta-hydroxylase), which blocks not only conversion of 11-deoxycortisol to cortisol but also conversion of 11-deoxycorticosterone (DOC) to corticosterone. DOC therefore accumulates, and the rising ACTH that accompanies falling cortisol drives still more precursor into the pathway, increasing DOC further. DOC is a weak mineralocorticoid that activates renal mineralocorticoid receptors, causing sodium retention (hypertension) and potassium wasting (hypokalemia) — and this occurs precisely when the drug is working, as shown by the falling UFC and improving cushingoid features. Because the drug is effective, it can be continued for cortisol control while the mineralocorticoid effects are managed (for example, with a mineralocorticoid receptor antagonist and potassium repletion).
Option A: Option A is incorrect because the hypertension and hypokalemia occur alongside a falling UFC and clinical improvement, indicating the drug is working rather than failing; the findings reflect DOC accumulation, not a laboratory error.
Option B: Option B is incorrect because hypertension with hypokalemia is the opposite of adrenal insufficiency, which causes hypotension and hyponatremia; this is mineralocorticoid excess.
Option C: Option C is incorrect because the findings are explained by DOC-mediated mineralocorticoid excess from metyrapone, not by residual ketoconazole effect on antihypertensive drug levels; moreover, raising antihypertensive levels would tend to lower, not raise, blood pressure.
Option E: Option E is incorrect because the patient is on metyrapone, not pasireotide, and hypertension with hypokalemia reflects DOC-driven mineralocorticoid excess rather than islet suppression or osmotic diuresis.
12. [CASE 3 — QUESTION 12]
Continuing with the same patient. Because of the troublesome DOC-mediated hypertension on metyrapone, she is switched to osilodrostat. After dose titration, she again develops hypokalemia, but this time it is accompanied by hypotension rather than hypertension. Which of the following best explains the different blood pressure pattern and the monitoring it requires?
A) Osilodrostat, like metyrapone, causes DOC accumulation, so the hypotension is unrelated to the drug and must reflect intercurrent dehydration; no specific monitoring is needed.
B) Osilodrostat inhibits CYP3A4 and raises the levels of her antihypertensive drugs, producing hypotension; the management is to reduce those antihypertensives, and no electrolyte monitoring is required.
C) Unlike metyrapone, osilodrostat inhibits both CYP11B1 (lowering cortisol) and CYP11B2 (aldosterone synthase), reducing aldosterone synthesis; the resulting aldosterone deficiency causes hypotension and hypokalemia — in contrast to the DOC-driven mineralocorticoid excess of metyrapone — so electrolytes (potassium, sodium) and blood pressure must be monitored at each dose titration, with attention also to QT prolongation and CYP2D6 interactions.
D) Osilodrostat inhibits CYP17A1, depleting androgens and lowering blood pressure through androgen deficiency; the monitoring required is serial testosterone measurement.
E) Osilodrostat is a direct arterial vasodilator at therapeutic concentrations, and the hypokalemia is a reflex consequence of compensatory aldosterone release; blood pressure should be monitored but potassium need not be.
ANSWER: C
Rationale:
Osilodrostat is a potent CYP11B1 (11-beta-hydroxylase) inhibitor that additionally inhibits CYP11B2 (aldosterone synthase). This dual inhibition distinguishes it from metyrapone, which selectively inhibits CYP11B1. With metyrapone, the proximal CYP11B1 block causes DOC accumulation and mineralocorticoid excess (hypertension and hypokalemia). With osilodrostat, the additional CYP11B2 inhibition reduces aldosterone synthesis, so the patient can develop aldosterone deficiency — producing hypotension and hypokalemia rather than hypertension. Electrolytes (potassium, sodium) and blood pressure must therefore be monitored at each dose titration, with additional attention to QT prolongation and to CYP2D6-mediated drug interactions, since osilodrostat is a moderate CYP2D6 inhibitor.
Option A: Option A is incorrect because osilodrostat does not produce the DOC-accumulation pattern of metyrapone; its CYP11B2 inhibition lowers aldosterone, and the hypotension is a direct consequence of its mechanism requiring monitoring, not incidental dehydration.
Option B: Option B is incorrect because osilodrostat is a CYP2D6 inhibitor and a CYP3A4 substrate, not a CYP3A4 inhibitor that raises antihypertensive levels; the hypotension reflects aldosterone deficiency, and electrolyte monitoring is required.
Option D: Option D is incorrect because osilodrostat's distinguishing action is CYP11B2 inhibition, not CYP17A1 inhibition; androgen deficiency is not the mechanism of its hypotension, and testosterone monitoring is not the relevant surveillance.
Option E: Option E is incorrect because osilodrostat is not a direct arterial vasodilator; its hypotension results from reduced aldosterone synthesis via CYP11B2 inhibition, and the hypokalemia reflects that aldosterone deficiency, so potassium monitoring is in fact essential.
13. [CASE 4 — QUESTION 13]
A 43-year-old woman with Cushing disease has persistent hypercortisolism after transsphenoidal surgery. A trial of octreotide produced no meaningful reduction in cortisol. The team now starts pasireotide, expecting a better response. Which of the following best explains why pasireotide is effective in Cushing disease whereas the first-generation somatostatin analog octreotide was not?
A) Corticotroph adenomas predominantly express somatostatin receptor subtype 5 (SSTR5) rather than SSTR2; pasireotide has high SSTR5 affinity and therefore suppresses adrenocorticotropic hormone (ACTH) secretion from the corticotroph, whereas octreotide acts mainly through SSTR2, which corticotroph adenomas express at low density.
B) Pasireotide is a glucocorticoid receptor antagonist that blocks cortisol signaling at peripheral tissues, while octreotide has no such activity; this receptor-blocking mechanism explains the difference.
C) Pasireotide directly inhibits adrenal CYP11B1, lowering cortisol synthesis, whereas octreotide has no adrenal enzyme-inhibiting activity; this adrenal action accounts for the efficacy difference.
D) Octreotide and pasireotide both act on SSTR2, but pasireotide reaches higher plasma concentrations and saturates SSTR2 more completely on corticotroph cells.
E) Pasireotide activates dopamine D2 receptors on corticotroph cells through cross-reactivity at the somatostatin binding site, providing a dopaminergic mechanism that octreotide lacks.
ANSWER: A
Rationale:
Corticotroph adenomas that cause Cushing disease predominantly express somatostatin receptor subtype 5 (SSTR5), with relatively low SSTR2 density. First-generation somatostatin analogs such as octreotide act mainly through SSTR2, which explains their limited efficacy in Cushing disease. Pasireotide is a pan-somatostatin receptor agonist with particularly high affinity for SSTR5; by activating the SSTR5 receptors predominantly expressed on corticotroph adenoma cells, pasireotide suppresses ACTH secretion and thereby reduces downstream adrenal cortisol production. This receptor-subtype mismatch — SSTR5-rich tumors versus an SSTR2-targeted drug — is precisely why octreotide fails and pasireotide succeeds.
Option B: Option B is incorrect because pasireotide is a somatostatin receptor agonist, not a glucocorticoid receptor antagonist; mifepristone is the glucocorticoid receptor antagonist, and pasireotide acts at the pituitary corticotroph rather than blocking cortisol peripherally.
Option C: Option C is incorrect because pasireotide does not inhibit adrenal CYP11B1; adrenal steroidogenesis inhibition is the mechanism of ketoconazole, metyrapone, and osilodrostat, whereas pasireotide acts at the pituitary via SSTR5.
Option D: Option D is incorrect because the efficacy difference is not explained by higher pasireotide concentrations saturating SSTR2; it is explained by pasireotide's affinity for SSTR5, the subtype corticotroph adenomas actually express, whereas octreotide targets the sparsely expressed SSTR2.
Option E: Option E is incorrect because pasireotide does not activate dopamine D2 receptors; its mechanism is somatostatin receptor agonism (notably SSTR5), and dopaminergic action is the separate mechanism of cabergoline.
14. [CASE 4 — QUESTION 14]
Continuing with the same patient. On pasireotide, her urinary free cortisol (UFC) falls by about 40% but remains above normal. The team adds cabergoline in an effort to achieve better control. Which of the following best explains the rationale for combining these two pituitary-directed agents at the corticotroph adenoma?
A) Cabergoline and pasireotide both act on somatostatin receptor subtype 5 (SSTR5), so adding cabergoline simply increases SSTR5 occupancy for a purely additive effect at the same receptor.
B) Cabergoline blocks adrenal steroidogenesis through CYP11B1 inhibition while pasireotide acts at the pituitary, so the combination attacks cortisol synthesis at two different adrenal enzymatic steps.
C) Cabergoline acts as a glucocorticoid receptor antagonist at peripheral tissues while pasireotide lowers ACTH at the pituitary, so the combination both reduces ACTH and blocks residual cortisol signaling.
D) Pasireotide suppresses ACTH through somatostatin receptor subtype 5 (SSTR5), while cabergoline suppresses ACTH through dopamine D2 receptors (D2R); because corticotroph adenomas can express both receptor types, engaging two independent inhibitory pathways can produce additive or complementary ACTH suppression in a tumor only partially controlled by either agent alone.
E) The two drugs are pharmacologically redundant because both ultimately lower cortisol, so adding cabergoline provides no mechanistic advantage and should not be used.
ANSWER: D
Rationale:
Pasireotide suppresses ACTH secretion by activating somatostatin receptor subtype 5 (SSTR5), the predominant somatostatin receptor on corticotroph adenomas. Cabergoline suppresses ACTH through a different receptor — the dopamine D2 receptor (D2R) — which corticotroph adenomas also express with variable density. Because the two drugs engage two independent inhibitory pathways converging on the same cell, combining them can produce additive or complementary ACTH suppression in a tumor only partially controlled by either agent alone; this combination strategy is used clinically in partial responders such as this patient.
Option A: Option A is incorrect because cabergoline does not act on SSTR5; it acts on D2R, so the combination engages two different receptors rather than increasing occupancy at a single shared receptor.
Option B: Option B is incorrect because cabergoline does not inhibit adrenal CYP11B1 or block steroidogenesis; it is a pituitary-directed dopamine agonist, so the combination is not an adrenal two-enzyme blockade.
Option C: Option C is incorrect because cabergoline is not a glucocorticoid receptor antagonist; that mechanism belongs to mifepristone, and cabergoline instead suppresses ACTH at the corticotroph through D2R.
Option E: Option E is incorrect because the drugs are not redundant; they act through distinct receptors (SSTR5 versus D2R) and can therefore provide complementary suppression, which is the mechanistic basis for combining them in partial responders.
15. [CASE 4 — QUESTION 15]
Continuing with the same patient. On the pasireotide-cabergoline combination her UFC improves further, but she develops new hyperglycemia with a fasting glucose of 188 mg/dL. The team plans to manage this while continuing the effective regimen and is choosing between a sulfonylurea and a glucagon-like peptide-1 (GLP-1) receptor agonist. Which of the following best explains why the GLP-1 receptor agonist is expected to retain efficacy while the sulfonylurea is blunted?
A) Sulfonylureas and GLP-1 receptor agonists act through the identical beta-cell pathway, but the GLP-1 receptor agonist reaches higher intracellular concentrations and overcomes somatostatin receptor inhibition by mass action.
B) Pasireotide activates somatostatin receptors on pancreatic beta cells — Gi-coupled receptors that lower cyclic AMP (cAMP) and suppress insulin secretion at a step downstream of the sulfonylurea's site of action, blunting sulfonylurea efficacy; GLP-1 receptor agonists act through Gs-coupled GLP-1 receptors that raise cAMP and stimulate glucose-dependent insulin secretion while suppressing glucagon, directly counteracting the somatostatin-driven cAMP reduction and so retaining efficacy.
C) Pasireotide raises beta-cell cAMP, which enhances sulfonylurea-stimulated insulin secretion; the GLP-1 receptor agonist is preferred only because it additionally promotes weight loss, not because of any signaling difference.
D) GLP-1 receptor agonists suppress insulin secretion through the same Gi-coupled pathway as pasireotide, while sulfonylureas stimulate it; the GLP-1 receptor agonist is preferred because lowering insulin reduces pasireotide-related hyperglycemia.
E) The sulfonylurea is blunted because pasireotide directly blocks the GLP-1 receptor, whereas the GLP-1 receptor agonist bypasses this by acting on the sulfonylurea receptor instead.
ANSWER: B
Rationale:
Pasireotide activates somatostatin receptors on pancreatic beta cells; these receptors are Gi-coupled, so they inhibit adenylyl cyclase, lower cyclic AMP (cAMP), and suppress insulin secretion. Sulfonylureas stimulate insulin release by closing ATP-sensitive potassium channels, but the somatostatin-driven reduction in cAMP acts downstream and dampens the resulting insulin exocytosis, blunting sulfonylurea efficacy. GLP-1 receptor agonists, by contrast, act through Gs-coupled GLP-1 receptors that raise cAMP and stimulate glucose-dependent insulin secretion while suppressing glucagon; by raising cAMP, they directly counteract the somatostatin-driven cAMP reduction, so they retain efficacy where the sulfonylurea is impaired. This signaling logic is the basis for preferring GLP-1 receptor agonists in pasireotide-induced hyperglycemia.
Option A: Option A is incorrect because sulfonylureas and GLP-1 receptor agonists do not act through an identical pathway; they engage different targets, and the advantage is mechanistic rather than a matter of mass-action concentration.
Option C: Option C is incorrect because pasireotide lowers rather than raises beta-cell cAMP, so it suppresses rather than enhances sulfonylurea-stimulated secretion; the GLP-1 receptor agonist's preference rests on a signaling difference, not solely on weight effects.
Option D: Option D is incorrect because GLP-1 receptor agonists stimulate (not suppress) insulin secretion through a Gs-coupled, cAMP-raising pathway; they do not share pasireotide's Gi-coupled inhibitory mechanism, and the benefit is increased glucose-dependent insulin secretion.
Option E: Option E is incorrect because pasireotide does not block the GLP-1 receptor, and GLP-1 receptor agonists do not act on the sulfonylurea receptor; the explanation lies in opposing effects on cAMP, not receptor cross-blockade.
16. [CASE 4 — QUESTION 16]
Continuing with the same patient. As her combination therapy brings cortisol toward the normal range, the team wants to anticipate the shared safety risk of effective Cushing disease treatment. Which of the following is the most important counseling and safety measure to implement at this stage?
A) Reassure her that adrenal insufficiency cannot occur because her ACTH-secreting tumor will always maintain adequate cortisol, so no special precautions are needed.
B) Instruct her to stop all therapy immediately if she feels fatigued, because fatigue always indicates dangerous overtreatment requiring permanent discontinuation.
C) Advise her that the main risk is mineralocorticoid excess, so she should restrict sodium and take a potassium-sparing diuretic prophylactically.
D) Tell her that the principal risk is hyperglycemia alone, so glucose monitoring is the only safety measure required as cortisol falls.
E) Teach her to recognize the symptoms of adrenal insufficiency (fatigue, nausea, hypotension, hyponatremia) — which can occur as cortisol falls from supraphysiologic toward normal even while biochemical values remain in the low-normal range — and provide a stress-dose hydrocortisone plan (oral hydrocortisone at illness onset; injectable hydrocortisone for vomiting or emergencies), since adrenal insufficiency is the shared risk of all effective Cushing disease therapies.
ANSWER: E
Rationale:
All effective treatments for Cushing disease carry a risk of adrenal insufficiency as cortisol falls from supraphysiologic toward normal or below-normal levels. Patients accustomed to cortisol excess may become symptomatic — fatigue, nausea, hypotension, hyponatremia — even when biochemical values are still within the low-normal range, because their tissues are adapted to high cortisol. The essential safety measure is to teach the patient to recognize adrenal insufficiency symptoms and to provide a stress-dose hydrocortisone plan: oral hydrocortisone at the onset of illness, and injectable hydrocortisone for vomiting or emergencies. This anticipatory counseling applies to pasireotide, cabergoline, and the steroidogenesis inhibitors alike.
Option A: Option A is incorrect because adrenal insufficiency can indeed occur during effective therapy; as ACTH and cortisol are suppressed, the tumor does not maintain adequate cortisol, so precautions are necessary.
Option B: Option B is incorrect because abruptly stopping all therapy for fatigue is not appropriate; fatigue should prompt evaluation for adrenal insufficiency and stress-dosing of hydrocortisone, not permanent discontinuation of effective treatment.
Option C: Option C is incorrect because the shared class risk at this stage is adrenal insufficiency from falling cortisol, not mineralocorticoid excess; sodium restriction and a potassium-sparing diuretic do not address the principal concern.
Option D: Option D is incorrect because, although hyperglycemia is a relevant pasireotide effect, the principal shared safety risk as cortisol normalizes is adrenal insufficiency, which requires symptom recognition and a stress-dose hydrocortisone plan, not glucose monitoring alone.
17. [CASE 5 — QUESTION 17]
A 58-year-old woman with Cushing syndrome and severe, difficult-to-control type 2 diabetes mellitus has failed transsphenoidal surgery and is not a candidate for further surgery. Her endocrinologist plans to start mifepristone (Korlym) primarily to address her hyperglycemia. Which of the following correctly identifies mifepristone's FDA-approved indication in this setting and its mechanism of action?
A) Mifepristone is approved as primary therapy to normalize urinary free cortisol (UFC) in Cushing disease, acting by reducing ACTH secretion from the corticotroph through restored negative feedback.
B) Mifepristone is approved for Cushing syndrome only when the cause is adrenal carcinoma, acting as an adrenal steroidogenesis inhibitor that blocks CYP11B1.
C) Mifepristone is approved for the management of hyperglycemia in adults with Cushing syndrome who have failed surgery or are not surgical candidates; it acts as a glucocorticoid receptor (GR) antagonist that blocks cortisol signaling at target tissues — improving glucose metabolism — without reducing cortisol secretion.
D) Mifepristone is approved for Cushing syndrome and lowers cortisol by inhibiting CYP11B1 in the adrenal cortex; its glucocorticoid receptor antagonism is an incidental off-target effect.
E) Mifepristone is approved for Cushing syndrome and functions as both a glucocorticoid receptor antagonist and a steroidogenesis inhibitor, lowering cortisol while also blocking peripheral glucocorticoid signaling.
ANSWER: C
Rationale:
Mifepristone (Korlym) is a synthetic glucocorticoid receptor (GR) antagonist approved by the FDA for the management of hyperglycemia secondary to Cushing syndrome in adults — including Cushing disease — who have failed surgery or are not surgical candidates. The approved indication is specifically hyperglycemia control, not the broader management of hypercortisolism, because mifepristone does not reduce cortisol secretion. Its mechanism is competitive antagonism at the glucocorticoid receptor at target tissues (particularly liver and skeletal muscle), which restores insulin sensitivity and improves glucose metabolism despite ongoing cortisol excess; it binds GR with approximately three times the affinity of cortisol.
Option A: Option A is incorrect because mifepristone does not reduce ACTH or restore negative feedback; ACTH and cortisol actually rise during therapy because GR blockade removes feedback, and the drug is not approved as a tool to normalize UFC.
Option B: Option B is incorrect because mifepristone's approval encompasses Cushing syndrome broadly, not only adrenal carcinoma, and it is a GR antagonist rather than a CYP11B1-inhibiting steroidogenesis inhibitor.
Option D: Option D is incorrect because mifepristone does not inhibit CYP11B1 or any adrenal steroidogenic enzyme; its action is entirely receptor-mediated GR antagonism, which is the approved mechanism, not an off-target effect.
Option E: Option E is incorrect because mifepristone does not inhibit steroidogenesis; as a GR antagonist it reduces glucocorticoid signaling at the receptor level while cortisol secretion actually increases, so it has no steroidogenesis-inhibiting component.
18. [CASE 5 — QUESTION 18]
Continuing with the same patient. Eight weeks after starting mifepristone, her fasting glucose has improved markedly, but laboratory testing now shows a markedly elevated serum cortisol, an elevated urinary free cortisol (UFC), and a high ACTH. Which of the following best explains these laboratory findings?
A) The elevated cortisol, UFC, and ACTH are the expected pharmacodynamic consequence of mifepristone: glucocorticoid receptor (GR) blockade eliminates cortisol's negative feedback on the hypothalamus and pituitary, so ACTH rises and drives increased cortisol secretion; these biomarkers therefore rise during therapy and cannot be used to judge efficacy or detect adrenal insufficiency.
B) The elevated cortisol indicates mifepristone treatment failure, because effective therapy should lower cortisol secretion, and an alternative agent should replace it.
C) The elevated cortisol reflects mifepristone's inhibition of hepatic cortisol clearance through CYP3A4, causing cortisol accumulation independent of any change in secretion.
D) The elevated ACTH indicates that mifepristone has been converted to a glucocorticoid receptor partial agonist, paradoxically stimulating the corticotroph to hypersecrete ACTH.
E) The elevated cortisol and ACTH indicate paradoxical stimulation of corticotroph tumor growth by mifepristone, warranting urgent pituitary MRI to assess for tumor enlargement.
ANSWER: A
Rationale:
Mifepristone is a glucocorticoid receptor (GR) antagonist that blocks cortisol action at target tissues without reducing cortisol secretion. Because GR blockade eliminates negative feedback at the hypothalamus and pituitary, ACTH rises and drives increased cortisol secretion; serum cortisol, UFC, and ACTH all rise during therapy. These elevations are the expected pharmacodynamic response, not a sign of treatment failure, and the biomarkers cannot be used to judge efficacy or to detect adrenal insufficiency. In this patient, the marked improvement in glucose confirms the drug is working as intended despite the rising cortisol.
Option B: Option B is incorrect because the elevated cortisol is the predictable result of GR blockade and does not indicate treatment failure; the clinical improvement in glucose demonstrates efficacy.
Option C: Option C is incorrect because mifepristone does not inhibit hepatic cortisol clearance to a clinically significant degree; the rising cortisol reflects increased HPA drive from lost feedback, not reduced cortisol catabolism.
Option D: Option D is incorrect because mifepristone is a GR antagonist, not a partial agonist, at therapeutic doses; it does not convert to an agonist that stimulates the corticotroph, and the ACTH rise results from lost negative feedback.
Option E: Option E is incorrect because direct corticotroph tumor stimulation by mifepristone is not a recognized mechanism; the ACTH and cortisol elevations result from removal of negative feedback, not from drug-induced tumor growth.
19. [CASE 5 — QUESTION 19]
Continuing with the same patient. The team needs to establish how they will judge whether mifepristone is controlling her disease over the coming months. Which of the following is the most appropriate approach to monitoring mifepristone efficacy?
A) Follow serial urinary free cortisol (UFC), targeting normalization, because a falling UFC is the most reliable indicator that mifepristone is controlling the disease.
B) Follow serum ACTH, targeting suppression, because effective mifepristone therapy restores negative feedback and lowers ACTH.
C) Follow late-night salivary cortisol, targeting normalization, because mifepristone reduces nocturnal cortisol secretion.
D) Follow clinical and metabolic endpoints — glucose control and HbA1c, blood pressure, body weight, and resolution of cushingoid features — because mifepristone is a glucocorticoid receptor antagonist that does not lower cortisol secretion; cortisol, UFC, and ACTH all rise during therapy and are uninterpretable as efficacy markers, so treatment adequacy must be judged clinically.
E) Follow serum cortisol, expecting it to fall below the normal range, because mifepristone produces a measurable decline in circulating cortisol that parallels clinical benefit.
ANSWER: D
Rationale:
Because mifepristone is a glucocorticoid receptor antagonist that blocks cortisol action without reducing its secretion, and because GR blockade removes negative feedback so that cortisol, UFC, and ACTH all rise during therapy, these biochemical markers are uninterpretable as efficacy endpoints. Treatment adequacy must instead be judged using clinical and metabolic endpoints: glucose control and HbA1c (mifepristone is indicated for hyperglycemia in Cushing syndrome), blood pressure, body weight, and resolution of cushingoid features. This is the established monitoring approach for mifepristone.
Option A: Option A is incorrect because mifepristone does not lower cortisol secretion, so UFC does not fall and in fact rises; it cannot be used to track efficacy.
Option B: Option B is incorrect because mifepristone does not suppress ACTH; ACTH rises because GR blockade removes negative feedback, so it is not a valid efficacy marker.
Option C: Option C is incorrect because mifepristone does not reduce cortisol secretion, so late-night salivary cortisol does not normalize and is uninterpretable in this setting.
Option E: Option E is incorrect because serum cortisol rises rather than falls during mifepristone therapy, so expecting it to fall below normal misrepresents the drug's pharmacology and would mislead efficacy assessment.
20. [CASE 5 — QUESTION 20]
Continuing with the same patient. A few months into therapy, she develops fatigue, nausea, light-headedness, and a blood pressure of 92/58 mmHg. A covering physician checks a serum cortisol, finds it elevated, and concludes that adrenal insufficiency is excluded; the physician also suggests adding ketoconazole to bring the high cortisol down. Which of the following is the most appropriate management?
A) Add ketoconazole to lower the elevated cortisol, since the high serum cortisol confirms ongoing hypercortisolism that requires steroidogenesis inhibition.
B) Recognize that adrenal insufficiency on mifepristone is a clinical diagnosis that cannot be excluded by a cortisol level (cortisol is elevated by design during GR blockade); treat the clinical adrenal insufficiency empirically with high-dose hydrocortisone, hold mifepristone, and do NOT add a steroidogenesis inhibitor, since combining it with GR blockade would further increase the risk of adrenal insufficiency.
C) Reassure the patient that the elevated cortisol excludes adrenal insufficiency, continue mifepristone unchanged, and attribute the symptoms to her diabetes.
D) Order a cosyntropin stimulation test and withhold all treatment until the result returns, since empiric glucocorticoid therapy would invalidate the diagnostic workup.
E) Increase the mifepristone dose, since worsening symptoms indicate inadequate glucocorticoid receptor blockade and a higher dose will relieve them.
ANSWER: B
Rationale:
In a patient on mifepristone, adrenal insufficiency is a clinical diagnosis and cannot be excluded by a cortisol level, because cortisol is expected to be elevated by design during GR blockade. This patient's fatigue, nausea, light-headedness, and hypotension are clinical signs of adrenal insufficiency despite the elevated cortisol. The correct management is to treat empirically with high-dose hydrocortisone (which can overcome the receptor blockade at sufficient doses), hold mifepristone, and crucially NOT add a steroidogenesis inhibitor such as ketoconazole — combining cortisol-synthesis blockade with GR antagonism would further increase the risk of adrenal insufficiency. Recognizing the clinical picture and acting on it, rather than being falsely reassured by the cortisol value, is the key teaching point.
Option A: Option A is incorrect because adding ketoconazole in a patient with clinical adrenal insufficiency would be dangerous, compounding glucocorticoid deficiency; the elevated cortisol is an expected pharmacodynamic finding, not evidence that more cortisol-lowering is needed.
Option C: Option C is incorrect because the elevated cortisol does not exclude adrenal insufficiency during GR blockade, and dismissing the symptoms as diabetes-related risks a serious adverse outcome.
Option D: Option D is incorrect because withholding empiric glucocorticoid while awaiting a cosyntropin stimulation test is unsafe in a symptomatic, hypotensive patient, and that test is not a reliable way to assess adrenal insufficiency during GR blockade; treatment should not be delayed.
Option E: Option E is incorrect because increasing the mifepristone dose would worsen, not relieve, the adrenal insufficiency; the symptoms reflect excessive glucocorticoid blockade at the tissue level, which calls for hydrocortisone and holding the drug, not more antagonism.
21. [CASE 6 — QUESTION 21]
A 61-year-old man with locally advanced adrenocortical carcinoma is started on mitotane. His oncologist counsels him that he will require a specific lifelong hormonal regimen for as long as he remains on the drug. Which of the following best explains the pharmacological basis for this requirement and the replacement that is needed?
A) Mitotane suppresses pituitary ACTH secretion through a central toxic effect, producing secondary adrenal insufficiency that requires glucocorticoid replacement only, because mineralocorticoid secretion is preserved through the renin-angiotensin system.
B) Mitotane induces CYP3A4 within the adrenal cortex, accelerating catabolism of endogenous cortisol and aldosterone; replacement with both glucocorticoid and mineralocorticoid is needed only to offset increased clearance, not because of adrenal destruction.
C) Mitotane blocks corticotropin-releasing hormone receptors in the hypothalamus, causing reversible functional adrenal atrophy; both hormones must be replaced temporarily, but adrenal function recovers after the drug is stopped.
D) Mitotane selectively destroys only the zona fasciculata, producing isolated glucocorticoid deficiency; the zona glomerulosa is spared, so mineralocorticoid replacement is unnecessary.
E) Mitotane is an adrenolytic agent that produces selective cytotoxic destruction of adrenocortical cells (via formation of reactive acyl chloride intermediates that alkylate adrenocortical proteins) and also inhibits multiple adrenal steroidogenic enzymes; because both the glucocorticoid- and mineralocorticoid-producing zones are destroyed, all patients on maintenance mitotane require lifelong glucocorticoid and mineralocorticoid replacement, often at higher-than-usual doses because mitotane's potent CYP3A4 and CYP2B6 induction accelerates corticosteroid metabolism.
ANSWER: E
Rationale:
Mitotane (o,p'-DDD) is an adrenolytic agent derived from the insecticide DDT that produces progressive cytotoxic destruction of the adrenal cortex through the formation of reactive acyl chloride intermediates that alkylate adrenocortical cell proteins; it also inhibits multiple adrenal steroidogenic enzymes including CYP11A1, CYP11B1, CYP11B2, and CYP17A1. Because this destruction and enzyme inhibition affect both the zona fasciculata (cortisol) and the zona glomerulosa (aldosterone), all patients on maintenance mitotane require lifelong glucocorticoid (hydrocortisone or equivalent) and mineralocorticoid (fludrocortisone) replacement. Replacement doses often need to be higher than usual because mitotane's potent CYP3A4 and CYP2B6 induction accelerates corticosteroid catabolism.
Option A: Option A is incorrect because mitotane's adrenal insufficiency results from direct adrenocortical destruction, not pituitary ACTH suppression (ACTH actually rises as cortisol falls), and mineralocorticoid replacement is required because the zona glomerulosa is also destroyed.
Option B: Option B is incorrect because, although CYP3A4 induction does accelerate corticosteroid metabolism, the primary reason for mandatory replacement is adrenocortical destruction, which permanently abolishes endogenous production rather than merely increasing clearance.
Option C: Option C is incorrect because mitotane does not block corticotropin-releasing hormone receptors; it acts directly on adrenocortical cells through cytotoxic and enzyme-inhibitory mechanisms, and the resulting insufficiency is structural and not reliably reversible after discontinuation.
Option D: Option D is incorrect because mitotane destroys all adrenocortical zones, including the zona glomerulosa; aldosterone deficiency and the need for mineralocorticoid replacement are well established and not pharmacologically spared.
22. [CASE 6 — QUESTION 22]
Continuing with the same patient. He takes warfarin for chronic atrial fibrillation. Four weeks after starting mitotane, his international normalized ratio (INR) has fallen from a therapeutic 2.4 to 1.3 despite no change in warfarin dose, and he reports increasing fatigue and light-headedness. Which of the following best explains these findings and the appropriate management?
A) Mitotane inhibited CYP2C9, raising warfarin levels and the INR; reduce the warfarin dose to prevent bleeding and reduce the glucocorticoid replacement dose because mitotane raises endogenous cortisol.
B) The falling INR reflects dietary vitamin K changes unrelated to mitotane; counsel on diet and attribute the fatigue to deconditioning.
C) Mitotane displaced warfarin from adipose stores, transiently raising the INR; hold warfarin for several days and keep replacement steroid doses unchanged.
D) Mitotane is a potent inducer of CYP3A4 and CYP2B6 (and induces CYP2C9), accelerating warfarin metabolism and lowering the INR — so the warfarin dose must be increased substantially with frequent INR monitoring; the same enzyme induction accelerates corticosteroid metabolism and, together with mitotane-induced adrenal destruction, means his glucocorticoid (and often mineralocorticoid) replacement doses must be increased to relieve the fatigue and light-headedness of inadequate replacement.
E) The findings indicate mitotane overdose causing both bleeding and adrenal crisis; stop mitotane permanently and reverse anticoagulation.
ANSWER: D
Rationale:
This question integrates mitotane's enzyme-induction profile with its adrenolytic effect in a single patient. Mitotane is a potent inducer of CYP3A4 and CYP2B6 and also induces CYP2C9. Warfarin's active S-enantiomer is metabolized chiefly by CYP2C9 and the R-enantiomer by CYP3A4, so mitotane accelerates warfarin clearance, lowers warfarin exposure, and drops the INR — here from 2.4 to 1.3. The warfarin dose must be increased substantially with frequent INR monitoring (every 2 weeks) until a new stable therapeutic INR is reached, which is especially important given the thrombotic risk of atrial fibrillation. Simultaneously, the same enzyme induction accelerates corticosteroid metabolism, and mitotane's adrenal destruction abolishes endogenous steroid production; together these explain his fatigue and light-headedness as inadequate replacement, so his glucocorticoid (and often mineralocorticoid) replacement doses must be increased — frequently doubled or tripled.
Option A: Option A is incorrect because mitotane induces rather than inhibits CYP2C9, so the INR falls and warfarin must be increased; mitotane also lowers, not raises, endogenous cortisol, so replacement must increase.
Option B: Option B is incorrect because the marked INR fall coincides with mitotane initiation and is explained by enzyme induction, not diet, and the fatigue reflects inadequate glucocorticoid replacement rather than deconditioning.
Option C: Option C is incorrect because mitotane lowers the INR through enzyme induction rather than raising it via adipose displacement; holding warfarin would worsen sub-therapeutic anticoagulation, and replacement doses need to increase.
Option E: Option E is incorrect because the picture is not overdose causing bleeding and crisis; the INR is sub-therapeutic (raising thrombotic, not bleeding, risk), and mitotane is the indicated therapy for adrenocortical carcinoma, so it should be continued with dose adjustments rather than stopped.
23. [CASE 6 — QUESTION 23]
Continuing with the same patient. His clinical course prompts the team to review the natural history of patients managed with bilateral adrenalectomy for Cushing disease — a different but related scenario. Consider a 46-year-old woman who underwent bilateral adrenalectomy for refractory Cushing disease 3 years ago and is maintained on hydrocortisone and fludrocortisone. She now presents with progressive darkening of her skin and oral mucosa, new headaches, early visual field changes, and a serum ACTH of 740 pg/mL, with MRI showing an enlarging invasive sellar mass. Which of the following best identifies this condition and its underlying mechanism?
A) This is Nelson syndrome — an aggressive, invasive ACTH-secreting corticotroph adenoma that develops after bilateral adrenalectomy because the loss of cortisol negative feedback drives unopposed ACTH hypersecretion and corticotroph tumor growth; the markedly elevated ACTH and the characteristic hyperpigmentation (from ACTH-driven melanocyte-stimulating activity) are clinical hallmarks.
B) This is recurrent Cushing syndrome from an ectopic ACTH-secreting tumor that developed after adrenalectomy; the hyperpigmentation reflects cortisol-driven melanocyte stimulation despite the absence of adrenal glands.
C) This is a nonfunctioning pituitary macroadenoma causing hypopituitarism; the elevated ACTH is a laboratory artifact and the mass should be observed.
D) This is pituitary apoplexy of a pre-existing adenoma triggered by the stress of adrenalectomy; the high ACTH and hyperpigmentation result from acute infarction releasing stored hormone.
E) This is primary adrenal insufficiency from inadequate replacement; the hyperpigmentation reflects undertreatment, and the sellar mass is incidental.
ANSWER: A
Rationale:
This is a classic presentation of Nelson syndrome: an aggressive, invasive ACTH-secreting corticotroph adenoma that develops after bilateral adrenalectomy performed for refractory Cushing disease. With the adrenal glands removed, cortisol production ceases and the negative feedback that normally restrains ACTH secretion and limits corticotroph tumor growth is permanently lost, driving unopposed ACTH hypersecretion (here, 740 pg/mL) and accelerated, often invasive tumor growth that produces headache and visual compromise. The striking hyperpigmentation of skin and mucosa is a hallmark, explained by ACTH's structural homology with melanocyte-stimulating hormone and consequent melanocortin receptor activation.
Option B: Option B is incorrect because the ACTH source is the pituitary corticotroph adenoma driven by lost feedback, not an ectopic tumor, and the patient has no adrenal glands to produce the cortisol invoked to explain melanocyte stimulation.
Option C: Option C is incorrect because the markedly elevated ACTH is genuine and central to the diagnosis, not an artifact, and the enlarging invasive mass is a functioning corticotroph adenoma requiring active management rather than observation.
Option D: Option D is incorrect because the clinical course is progressive tumor growth with sustained ACTH hypersecretion over years, not the abrupt presentation of pituitary apoplexy from acute infarction.
Option E: Option E is incorrect because the markedly elevated ACTH with an enlarging invasive sellar mass indicates corticotroph tumor growth, not simply inadequate steroid replacement, and the mass is not incidental.
24. [CASE 6 — QUESTION 24]
Continuing with the same patient. For the woman with established Nelson syndrome whose invasive corticotroph adenoma is not fully resectable, the team considers the full range of management options. Which of the following best describes the appropriate management approach and the rationale for the medical therapies used?
A) Increase her hydrocortisone and fludrocortisone replacement doses, because Nelson syndrome is caused by inadequate steroid replacement and higher doses will suppress the tumor.
B) Pursue chemotherapy with mitotane alone, because mitotane suppresses corticotroph ACTH secretion directly and is the established first-line therapy for Nelson syndrome.
C) Use a combination of tumor-directed treatment (repeat transsphenoidal surgery and/or radiotherapy) and medical therapy to suppress ACTH, where pasireotide acts via somatostatin receptor subtype 5 (SSTR5) and cabergoline acts via dopamine D2 receptors (D2R) — both expressed on corticotroph adenomas — to reduce ACTH secretion and help control tumor activity, with temozolomide reserved for aggressive tumors that fail other measures; the realistic goal is ACTH reduction and tumor control rather than restoration of normal feedback, which cannot occur without adrenal glands.
D) Administer a glucocorticoid receptor antagonist such as mifepristone, because blocking glucocorticoid receptors will lower ACTH and shrink the corticotroph adenoma.
E) Observe with serial imaging only, because Nelson syndrome tumors are indolent and medical or surgical therapy does not alter their course.
ANSWER: C
Rationale:
Management of an invasive, not-fully-resectable corticotroph adenoma in Nelson syndrome combines tumor-directed treatment — repeat transsphenoidal surgery and/or radiotherapy (stereotactic or fractionated) — with medical therapy to suppress ACTH. Corticotroph adenomas can express somatostatin receptor subtype 5 (SSTR5) and dopamine D2 receptors (D2R), so pasireotide (via SSTR5) and cabergoline (via D2R) can reduce ACTH secretion and help control tumor activity; temozolomide is reserved for aggressive or malignant tumors that fail other measures. The realistic therapeutic goal is reduction of ACTH and control of tumor progression rather than restoration of normal HPA feedback, which is impossible without adrenal glands.
Option A: Option A is incorrect because Nelson syndrome is not caused by inadequate steroid replacement; it results from loss of cortisol negative feedback driving corticotroph tumor growth, and increasing replacement does not suppress the tumor.
Option B: Option B is incorrect because mitotane is an adrenolytic agent used principally for adrenocortical carcinoma and is not a first-line therapy that directly suppresses corticotroph ACTH secretion in Nelson syndrome; the patient also has no adrenal glands for mitotane to act upon.
Option D: Option D is incorrect because mifepristone is a glucocorticoid receptor antagonist that blocks cortisol action peripherally; it does not lower ACTH (and would tend to raise it) and does not shrink the corticotroph adenoma.
Option E: Option E is incorrect because Nelson syndrome tumors can be aggressive and invasive, as in this patient, and do warrant active surgical, radiotherapeutic, and medical management rather than observation alone.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.